When we’re trying to fight against an adversary that is as strong and full of tricks as cancer, what we need to do is look for points of vulnerability – Achilles heels. We all remember, of course, that the mother of Achilles dipped him in the River Styx when he was a tiny boy, […]
Articles
The publicity material for M. D. Anderson in Houston, Texas, which is perhaps the leading cancer treatment center in the United States, frequently includes a statement to the effect that they are committed to “ending cancer.” That statement puts me in mind of maps dating from the first century AD, in which large unexplored areas […]
One would think that it would take a person of normal intelligence about half a minute to conclude that lures such as the ones below could not possibly be on the up and up. Here’s one. It starts out with a note from Christine O’Brien. “The Sovereign Investor Daily A brand new, ‘Alzheimer’s vaccine’ […]
Way back in April 2018, the World Health Organization issued its Thirteenth General Programme of Work, which attracted a certain amount of notice at the time, but was certainly not treated as front-page news. The GPW 13, as WHO called it, was centered on three ambitious targets – worthy, but in the view of […]
This weekend I started seeing new questions about a Motley Fool pitch, and it turns out to be a new one that I haven’t covered before. The ad is for Motley Fool Rule Breakers, the growth-stock service helmed by David Gardner, and it’s apparently for a stock that he has recommended twice recently. Here’s a […]
What set me off on this rant was the very first comment on the piece that posted on January 31st, “Looking Backward – And a Peek in the Other Direction.” Here’s the comment: “Thanks, Doc. Hope you will comment on the news out of Israel this week: https://www.jpost.com/HEALTH-SCIENCE/A-cure-for-cancer-Israeli-scientists-say-they-think-they-found-one-578939” Naturally, I looked, and what I found […]
Chances are not many of us observed New Year’s Eve with celebratory toasts to the glorious year gone by. Rather, we bid goodbye to 2018 and hoped 2019 would be a better year – for ourselves, our near and dear, our country, and our planet. However, as I wade through the volumes of healthcare-related stuff […]
Most of the attention in the media is now focused on the several forms of cancer treatment grouped under the flattering term “Precision Medicine.” I find that the term raises my skepticism index just a bit; it’s like eating establishments labeling themselves “Gourmet Restaurants,” the implication being that joints not so identified are just […]
The plan was for Doc Gumshoe to fix his gaze on the hype around Delta 8 as the ultimate banned cancer cure, which he will definitely get around to. But the volume of comments and queries that “Cancer: The Lay of the Land in 2018” was such that I have little choice but to […]
and has actually been shown to reduce the size of tumors and may be another way of treating cancer. Thanks Travis, this was put out by Health Media
Putting the name of this imperious disease in the title of my homily places a weighty responsibility on me. Who am I to attempt to put forth relevant information and sensible opinions on this topic, the mere mention of which makes most normal folk distinctly uneasy? But I probably pay more attention to […]
Andrew Snyder has been on the editorial team of a bunch of different Agora-affiliated newsletters over the years, and is now helming his own little offshoot called Manward Press — a publishing imprint that aims to help men reach “true fulfillment” by focusing on “Liberty, Know-how and connections” … though, of course, to sell newsletters […]
10/28 update: this article is about a week old, but the teaser ads have changed a bit — the newsletter is now also being pitched under the headline, “Has this Maine town bottled the fountain of youth?” and it’s now also going out under the name Dr. Richard Robinson, who apparently works on the newsletter […]
That’s a mysterious headline, right? The pitch we’re looking at today is from Dave Lashmet at Stansberry, who’s selling his Stansberry Venture newsletter for $5,000 — and the carrot he’s dangling to get you to subscribe is this “most disruptive biotech discovery” … which, it turns out, is a form of radiation therapy that, in […]
There is little that makes investors (and human beings, frankly) perk up their ears more quickly than talk of a “cancer cure” … each of us has either been touched personally by cancer, or seen friends or loved ones hurt or killed by one of the many forms of this ugly disease, and we know […]
[ed note: Michael Jorrin is a longtime medical writer (not a doctor) who covers health and medical topics and trends for our readers, generally without an investment thesis. His words are his own, enjoy!] In the Doc Gumshoe blog about cancer that appeared in June of 2013 (you can check it out here), I commented […]
We’ve got a good teaser to solve today, but first — a quick plea: This will be our final week of “Gumshoe Gives Back” this year — we will be donating at least half of all the membership contributions received through the rest of this week (until the end of the day on Friday, 12/12) […]
[ed note: Michael Jorrin is not a doctor but we like to call him “Doc Gumshoe,” he writes non-investment pieces for us about medical hype and health issues from time to time — today he indulged me by taking on a pitch from a health newsletter that caught my eye] The promotional piece – endless […]
Today we’re sharing another piece from our medical contributor, “Doc Gumshoe” — we have added the stock tickers to the companies he mentions for your researching convenience, but this survey of the state of cancer research — which will hopefully be good background help to folks trying to understand the basic science behind pitches for […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
SpaceX now, mostly, though there's plenty of competition. The teaser for this from Ray Blanco has run under a bunch o...
I don't know what 5G companies they are talking about.... I wasn't willing to pay the $49 dollars to find out LOL.I wo...
Same story received in mail today or yesterday promoting the same Technology Profits Confidential newsletter. This time ...